Pattern and quality of care for rare head and neck cancers treated in expert centres: the experience of the registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN).

Authors

A Trama, L Licitra, C Bergamini, M Gil Sanjines, S Bonfarnuzzo, E Orlandi, B Vischioni, M Tagliabue, R De Berardinis, M Ansarin, V Manciocco, F Nardozza, G Mercante, A Mirabile, G Mari, F Gaino, P de Franco, E Cavalera, V Gregorc, V Valentini, P Bonomo, M Ferrari, L D Locati, J Galli, L Sacchetto, S Cavalieri, L Botta

Published in

ESMO open. Volume 11. Issue 10. Pages 108537. Sep 22, 2026. Epub Sep 22, 2026.

Abstract

Rare head and neck cancers (HNCs), including sinonasal cancers (SNC), nasopharyngeal cancers (NPC), and salivary gland cancers (SGC), are biologically diverse and infrequent, resulting in limited high-quality evidence to guide clinical management. This study evaluated real-world patterns and quality of care in Italy for these rare HNCs within the European Reference Network for Rare Adult Solid Cancers (EURACAN) registry.
Data from 795 adult patients diagnosed or managed at Italian expert centres between 2018 and 2024 with rare HNCs (152 SNC, 201 NPC, and 442 SGC) were analysed. Key indicators assessed included diagnostic completeness, adherence to European clinical practice guidelines, and timeliness of treatment. Analyses were stratified by tumour type and care setting.
Most patients presented with locally advanced disease (70% SNC, 74% NPC, and 50% SGC). Epstein-Barr virus testing was carried out in 80% of NPC cases. Treatment approaches were heterogeneous, especially for SNC, where multimodal therapy varied widely. Guidelines deviations were common: ∼50% of patients with localised SGC and 67% of those with localised NPC did not receive guideline-recommended treatments. Treatment delays were frequent, with 48%-77% of patients failing to initiate treatment within recommended timeframes. These delays were predominantly associated with interhospital referral pathways and were more pronounced in patients requiring multimodal treatments.
This registry-based analysis reveals substantial variability in treatment strategies and frequent treatment delays for rare HNCs, even within expert centres. Improving referral coordination, adherence to guidelines, and timely initiation of treatment remain critical. The EURACAN registry represents a valuable tool for benchmarking and enhancing care quality, supporting evidence-informed treatment decisions for these rare and complex cancers.

PMID:
42772165
Bibliographic data and abstract were imported from PubMed on 23 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.